
Potassium indol-3-yl sulfate | CAS:2642-37-7
Potassium indol-3-yl sulfate
- Name:Potassium indol-3-yl sulfate
- CAS:2642-37-7
- Synonyms:Indol-3-ol, potassium sulfate; Indol-3-yl sulfate, potassium salt; Indoxyl sulfate potassium salt
- Molecular Formula:C8H6NO4S.K
- Molecular Weight:251.30
- EINESC:220-145-5
Description
Properties
没有数据 | 没有数据 |
---|
Safety
没有数据 | 没有数据 |
---|
SDS
Source | SDS/MSDS Samples |
---|---|
Alfa-Aesar | View & Download |
Sigma-Aldrich | View & Download |
Matrix | View & Download |
Synthetic Route
Name | CAS |
---|
More
Articles
Peer-Reviewed Papers
Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation.Sai Vikram Vemula et al.Antiviral research, 139, 161-170 (2016-11-28)
Ingenol-3-Angelate Suppresses Growth of Melanoma Cells and Skin Tumor Development by Downregulation of NF-kappaB-Cox2 SignalingWang D and Liu P Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 24, 486-486 (2018)
Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites.Hao Guo et al.Science (New York, N.Y.), 370(6516) (2020-10-31)
Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir.Jason Neidleman et al.eLife, 9 (2020-09-30)
Quantifying the lagged Poincaré plot geometry of ultrashort heart rate variability series: automatic recognition of odor hedonic tone.M Nardelli et al.Medical & biological engineering & computing, 58(5), 1099-1112 (2020-03-13)
Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion LymphomaZhou F, et al. Molecular Cancer Therapeutics (2017)
Mian Yu et al.Journal of controlled release : official journal of the Controlled Release Society, 304, 242-258 (2019-05-10)Cancer-Immunotherapy was the most exciting topic. However, either insensitivity due to singleness of therapeutic target or immune evasion leads to the failure of the treatment. Ingenol-3-mebutate (I3A) can inhibit cancer through synergy between immunotherapy and chemotherapy, however, the speculation and...
Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo.Dawei Zhou et al.Science advances, 6(29), eaba1941-eaba1941 (2020-08-25)
Development of a solid-phase extraction method with simple MEKC-UV analysis for simultaneous detection of indole metabolites in human urine after administration of indole dietary supplement.Apichai Phonchai et al.Talanta, 174, 314-319 (2017-07-26)
Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.Pargol Hashemi et al.EMBO molecular medicine, 10(2), 160-174 (2017-12-17)
Dopamine receptor antagonists as potential therapeutic agents for ADPKD.Parama Paul et al.PloS one, 14(5), e0216220-e0216220 (2019-05-07)
Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.Judith Grau-Expósito et al.PLoS pathogens, 15(8), e1007991-e1007991 (2019-08-20)
Tissue memory CD4+ T cells expressing IL-7 receptor-alpha (CD127) preferentially support latent HIV-1 infection.Feng Hsiao et al.PLoS pathogens, 16(4), e1008450-e1008450 (2020-05-01)
Rapid measurement of indole levels in Brassica vegetables using one millilitre binary organic extraction solvent and capillary electrophoresis-UV analysis.Suparman et al.Phytochemical analysis : PCA, 31(4), 522-530 (2020-01-09)
Notch3/VEGF-A axis is involved in TAT-mediated proliferation of pulmonary artery smooth muscle cells: Implications for HIV-associated PAH.Ming-Lei Guo et al.Cell death discovery, 4, 22-22 (2018-08-16)
Effects of αTAT1 and HDAC5 on axonal regeneration in adult neurons.Shen Lin et al.PloS one, 12(5), e0177496-e0177496 (2017-05-16)
RasGRPs are targets of the anti-cancer agent ingenol-3-angelate.Xiaohua Song et al.PloS one, 8(8), e72331-e72331 (2013-08-31)
Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE-/- mice.Yunci Ma et al.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 113, 108753-108753 (2019-03-12)
Remarks
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
Name | CAS |
---|

Related Products
Related News
Question
Hot Tags
Inquiry
Fill in related informations ;please!
- Please fill in product name !
- CAS
- Please fill in your company information correctly!
- Please fill in liaison information correctly!
- Please fill in your telephone number correctly!
- Please fill in your email correctly!
- Please describe the problem of products!